Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Blood
    March 2026
  1. DERMER K, Richardson AI
    Pediatric acute erythroid leukemia with NUP98::KDM5A fusion.
    Blood. 2026;147:1237.
    >> Share

  2. MUJOLLARI J, Estruch M, Khadgawat P, Choudhary S, et al
    The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML.
    Blood. 2026;147:1229-1236.
    >> Share

  3. DI GIACOMO D, Polonen P, Bardelli V, Kimura S, et al
    Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemia.
    Blood. 2026 Mar 6:blood.2025031402. doi: 10.1182/blood.2025031402.
    >> Share

  4. PLATZBECKER AS, Georgi JA, Middeke JM, Sockel K, et al
    Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial.
    Blood. 2026;147:1098-1110.
    >> Share

  5. KNAPPER S, Dillon LW, Babu M, Thomas A, et al
    CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.
    Blood. 2026;147:1048-1057.
    >> Share

  6. RHEIN S, Cakmak-Gorur N, Grunert C, Al-Tabatabaee S, et al
    A CD22-specific T-cell receptor enables effective adoptive T-cell therapy for B-cell malignancies.
    Blood. 2026;147:1058-1069.
    >> Share

  7. BECILLI M, Merli P, Algeri M, Del Bufalo F, et al
    Anti-CD7 fratricide-resistant chimeric antigen receptor T cells for relapsed/refractory acute myeloid leukemia.
    Blood. 2026 Mar 3:blood.2025032299. doi: 10.1182/blood.2025032299.
    >> Share

    February 2026
  8. PARFENOVA EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, et al
    Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells.
    Blood. 2026 Feb 26:blood.2025031202. doi: 10.1182/blood.2025031202.
    >> Share

  9. HIMONAS E, de Beauchamp L, Zerbst D, Desmares-Romain E, et al
    A metabolism-specific drug-repurposing screen reveals itraconazole as a potent OXPHOS inhibitor in acute myeloid leukemia.
    Blood. 2026 Feb 24:blood.2024027853. doi: 10.1182/blood.2024027853.
    >> Share

  10. ATTARDI E, Gray N, Lewis S, Boals M, et al
    Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.
    Blood. 2026;147:897-901.
    >> Share

  11. LING T, O'Brien C, St-Germain JR, Rondeau V, et al
    Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation.
    Blood. 2026;147:863-876.
    >> Share

  12. TURKALJ S, Radtke FA, Stoilova B, Mecklenbrauck R, et al
    Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
    Blood. 2026;147:613-632.
    >> Share

    January 2026
  13. RANASINGHE D, Lin WY, Fordham SE, Alharbi AA, et al
    Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
    Blood. 2026 Jan 29:blood.2025031266. doi: 10.1182/blood.2025031266.
    >> Share

  14. PINTON A, Courtois L, Delafoy M, Bonnet MF, et al
    Homeodomain-driven oncogenic diversion to a TCRgammadelta phenotype in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2026 Jan 27:blood.2025030626. doi: 10.1182/blood.2025030626.
    >> Share

  15. GOTLIB J
    Introduction to a How I Treat series on chronic myeloid leukemia.
    Blood. 2026;147:319-320.
    >> Share

  16. MAURO MJ
    How I treat advanced phases of CML.
    Blood. 2026;147:369-378.
    >> Share

  17. SOVERINI S, Castagnetti F
    How I evaluate and treat resistance and relapse in CML.
    Blood. 2026;147:337-346.
    >> Share

  18. LEYTE-VIDAL A, Shah NP
    How I individualize frontline treatment for chronic-phase CML.
    Blood. 2026;147:329-336.
    >> Share

  19. POPESCU B, Jones MF, Piao M, Tran E, et al
    Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.
    Blood. 2026;147:276-289.
    >> Share

  20. SHARPE-DAVIDSON WF, Wan YO
    Acute promyelocytic leukemia diagnosed on soft tissue biopsy: a rare extramedullary presentation.
    Blood. 2026;147:215.
    >> Share

  21. GUARNERA L, Wahida A, Gurnari C, Hutter S, et al
    Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.
    Blood. 2026;147:197-208.
    >> Share

  22. DOHNER H, Spath D, Saadati M, Fiedler W, et al
    Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
    Blood. 2026 Jan 5:blood.2025030722. doi: 10.1182/blood.2025030722.
    >> Share

  23. KEESHAN K
    Fetal defense against leukemia: a developmental shield.
    Blood. 2026;147:7-8.
    >> Share

  24. WEI AH, Iland HJ, DiNardo CD, Reynolds J, et al
    Measurable residual disease intervention in AML: a new therapeutic horizon.
    Blood. 2026;147:13-23.
    >> Share

  25. MENDOZA-CASTREJON J, Yang W, Denby E, Wang HC, et al
    Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.
    Blood. 2026;147:61-72.
    >> Share

    December 2025
  26. NISHIMURA K, Isobe T, Shigehiro T, Nomura M, et al
    Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.
    Blood. 2025 Dec 29:blood.2024026928. doi: 10.1182/blood.2024026928.
    >> Share

  27. SIMON F, Ligtvoet R, Bohn JP, Nosslinger T, et al
    Acalabrutinib treatment for older (aged >/=80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
    Blood. 2025;146:3153-3162.
    >> Share

  28. AL-SAWAF O, Locher BN, Christen F, Hablesreiter R, et al
    The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia.
    Blood. 2025 Dec 23:blood.2025029905. doi: 10.1182/blood.2025029905.
    >> Share

  29. WILSON NK, Gottgens B
    Breaking the silence: restoring CEBPA to fight leukemia.
    Blood. 2025;146:3014-3015.
    >> Share

  30. FLEMING TJ, Antoszewski M, Lambo S, Gundry MC, et al
    CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.
    Blood. 2025;146:3019-3035.
    >> Share

  31. DELAFOY M, Bonnet MF, Lengline E, Cieslak A, et al
    LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/beta-catenin vulnerability in T-ALL.
    Blood. 2025;146:3036-3049.
    >> Share

  32. CORTES JE, Hughes TP, Wang J, Kim DW, et al
    Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
    Blood. 2025 Dec 15:blood.2025029210. doi: 10.1182/blood.2025029210.
    >> Share

  33. ZHANG L, Kang H, Valerio M, Hoang DH, et al
    Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia.
    Blood. 2025 Dec 15:blood.2025029875. doi: 10.1182/blood.2025029875.
    >> Share

  34. CLOOS J, Valk PJM, Thiede C, Dohner K, et al
    2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
    Blood. 2025 Dec 15:blood.2025031480. doi: 10.1182/blood.2025031480.
    >> Share

  35. MEYER E, Salhotra A, Gandhi A, Pantin J, et al
    Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.
    Blood. 2025 Dec 12:blood.2025031313. doi: 10.1182/blood.2025031313.
    >> Share

  36. SOUTO FILHO JTD, Paulo AB
    Promyelocyte maturation arrest after rituximab-induced late-onset neutropenia mimicking acute promyelocytic leukemia.
    Blood. 2025;146:3003.
    >> Share


  37. Marchand T, Lamy T, Loughran TP Jr. A modern view of LGL leukemia. Blood. 2024;144(18):1910-1923.
    Blood. 2025;146:2844.
    >> Share

  38. SHANMUGANATHAN N, Yeung DT, Wadham C, Fernandes A, et al
    Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
    Blood. 2025;146:2821-2832.
    >> Share

  39. PAN J, Zhao L, Zhang Y, Seery S, et al
    Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.
    Blood. 2025;146:2745-2757.
    >> Share

    November 2025

  40. Yeung DT, Shanmuganathan N, Reynolds J, et al; Australasian Leukaemia and Lymphoma Group. Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study. Blood. 2024;144(19):1993-2001.
    Blood. 2025;146:2729.
    >> Share

  41. PARISI X, Loghavi S
    NPM1-mutated acute myeloid leukemia with marked erythroid and megakaryocytic differentiation.
    Blood. 2025;146:2612.
    >> Share

  42. RAJ R, Catueno S, Gibson A, McCall D, et al
    FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.
    Blood. 2025;146:2608-2611.
    >> Share

  43. BUECHNER J, Poetschger U, Bader P, Yesilipek MA, et al
    Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT.
    Blood. 2025 Nov 19:blood.2025030951. doi: 10.1182/blood.2025030951.
    >> Share


  44. Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
    Blood. 2025;146:2493.
    >> Share

  45. AL-SAWAF O, Furstenau M, Giza A, Robrecht S, et al
    The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
    Blood. 2025;146:2406-2416.
    >> Share

  46. CHEN C, Cai J, Wu X, Hu Q, et al
    Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL.
    Blood. 2025;146:2417-2427.
    >> Share

  47. AZEVEDO RS, Jabbour E, Kantarjian HM, Lavu S, et al
    Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
    Blood. 2025 Nov 10:blood.2025030498. doi: 10.1182/blood.2025030498.
    >> Share

  48. STELLJES M, Middeke JM, Bug G, Wagner-Drouet EM, et al
    Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial.
    Blood. 2025;146:2293-2305.
    >> Share

  49. KAWANO G, Ikeda R, Ishihara D, Shima T, et al
    Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells.
    Blood. 2025 Nov 5:blood.2025030209. doi: 10.1182/blood.2025030209.
    >> Share

    October 2025
  50. KRUER TL, Quintana A, Newman H, Ferrall-Fairbanks M, et al
    XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
    Blood. 2025;146:2244-2258.
    >> Share

  51. BURGER JA, Barr PM, Robak T, Owen C, et al
    Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
    Blood. 2025;146:2168-2176.
    >> Share

  52. SEMBA Y, Yamauchi T, Bauer DE, Ogawa S, et al
    The XPO7-NPAT axis represents key vulnerabilities in TP53-mutated acute myeloid leukemia.
    Blood. 2025 Oct 29:blood.2025028918. doi: 10.1182/blood.2025028918.
    >> Share

  53. FETSCH V, Schwobel LF, Ozyerli-Goknar E PhD, Stell AV, et al
    Menin inhibition enhances graft-versus-leukemia effects by T-cell activation and endogenous retrovirus induction in AML.
    Blood. 2025 Oct 27:blood.2025029712. doi: 10.1182/blood.2025029712.
    >> Share

  54. BOISSEL N, Chevret S, Rigal-Huguet F, Leguay TT, et al
    Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
    Blood. 2025 Oct 24:blood.2025029611. doi: 10.1182/blood.2025029611.
    >> Share

  55. DUNCAVAGE E, Spencer D
    Leukemic fusion: partners and mutations shape NUP98r leukemia.
    Blood. 2025;146:2017-2018.
    >> Share

  56. SHADMAN M, Davids MS
    How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.
    Blood. 2025;146:2029-2036.
    >> Share

  57. SHI Y, Jiang Q, Li L, Zuo Y, et al
    Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1.
    Blood. 2025;146:2088-2101.
    >> Share

  58. LASZIG S, Diederichs A, Salzmann-Manrique E, Schuschel K, et al
    CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial.
    Blood. 2025 Oct 21:blood.2025030775. doi: 10.1182/blood.2025030775.
    >> Share

  59. LAM K, Kim YJ, Tan EL, Ong CM, et al
    The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia.
    Blood. 2025 Oct 20:blood.2024026749. doi: 10.1182/blood.2024026749.
    >> Share

  60. THAKUR RK, Karlsson G
    Insights from Single-cell Omics: Cellular Heterogeneity as a Foundation of Clinical Outcome in Chronic Myeloid Leukemia.
    Blood. 2025 Oct 17:blood.2025029011. doi: 10.1182/blood.2025029011.
    >> Share

  61. HANTEL A, Wang Y, Cronin A, Khan I, et al
    Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
    Blood. 2025 Oct 16:blood.2025030741. doi: 10.1182/blood.2025030741.
    >> Share

  62. CHIRIAC R
    Acute myeloid leukemia mimicking mature lymphoid morphology.
    Blood. 2025;146:2005.
    >> Share

  63. GUO M, Memis T, Ehrmann AS, Pittrof A, et al
    A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.
    Blood. 2025;146:1936-1949.
    >> Share

  64. SHI M, Rech KL
    T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
    Blood. 2025;146:1868.
    >> Share

  65. OTHMAN J, Potter N, Freeman SD, McCarthy N, et al
    Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
    Blood. 2025;146:1862-1867.
    >> Share

  66. PASTOORS D, Havermans M, Mulet-Lazaro R, Smeenk L, et al
    MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.
    Blood. 2025 Oct 8:blood.2025028914. doi: 10.1182/blood.2025028914.
    >> Share

  67. SCHROEDER B, Yuan CM, Wang HW, Mohindroo C, et al
    Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.
    Blood. 2025 Oct 8:blood.2025031243. doi: 10.1182/blood.2025031243.
    >> Share

  68. BROWN JR, Nguyen B, Desikan SP, Won H, et al
    Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2025 Oct 7:blood.2024027009. doi: 10.1182/blood.2024027009.
    >> Share

  69. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
    Blood. 2025;146:1664-1676.
    >> Share

    September 2025
  70. PENTER L, Maurer K, Cieri N, Lu W, et al
    Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
    Blood. 2025 Sep 30:blood.2025029121. doi: 10.1182/blood.2025029121.
    >> Share

  71. NEDUMANNIL R, Ashby M, Rowland J, Malherbe JAJ, et al
    Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.
    Blood. 2025;146:1625-1629.
    >> Share

  72. DEREVYANKO PK, Swart LE, Mata Casimiro LD, van Oort A, et al
    Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia.
    Blood. 2025 Sep 24:blood.2025028988. doi: 10.1182/blood.2025028988.
    >> Share

  73. MATEOS-JAIMEZ J, Vidal Crespo A, Charalampopoulou S, Fernandez Perez R, et al
    INCREASED LEF1 PROTEIN LEVELS AND ISOFORM SWITCHING DRIVE CELL PROLIFERATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
    Blood. 2025 Sep 22:blood.2025030129. doi: 10.1182/blood.2025030129.
    >> Share

  74. NEVEN Q, Arfeuille C, Caye-Eude A, Durand P, et al
    The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.
    Blood. 2025 Sep 19:blood.2025029916. doi: 10.1182/blood.2025029916.
    >> Share

  75. ANDRICOVICH J, Lap CJ, Tzatsos A
    Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.
    Blood. 2025;146:1493-1510.
    >> Share

  76. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
    Blood. 2025;146:1276-1285.
    >> Share

  77. MARTINEZ TC, Jotte MRM, Khan S, Stoddart A, et al
    CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways.
    Blood. 2025 Sep 8:blood.2024026815. doi: 10.1182/blood.2024026815.
    >> Share

  78. VENKATESH H, Granados Centeno E, Luo Q, Arroyo M, et al
    Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.
    Blood. 2025 Sep 4:blood.2024028194. doi: 10.1182/blood.2024028194.
    >> Share

  79. PAPAPETROU EP
    Breaking ribosomes to fight leukemia.
    Blood. 2025;146:1155-1156.
    >> Share

  80. DAMASKOU A, Wilson R, Gozdecka M, Giotopoulos G, et al
    Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.
    Blood. 2025;146:1239-1252.
    >> Share

  81. GHOBADI A, Aldoss I, Maude SL, Bhojwani D, et al
    Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
    Blood. 2025;146:1163-1173.
    >> Share

  82. REN H, Elliott N, Lye B, Sharif Shohan MU, et al
    Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.
    Blood. 2025 Sep 3:blood.2025029302. doi: 10.1182/blood.2025029302.
    >> Share

    August 2025
  83. CRISPINO JD
    Meddling with METTL3 in acute megakaryoblastic leukemia.
    Blood. 2025;146:1035-1036.
    >> Share

  84. GEYER MB, DeWolf S, Mi X, Weis K, et al
    CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia.
    Blood. 2025 Aug 27:blood.2025029532. doi: 10.1182/blood.2025029532.
    >> Share

  85. O'BRIEN C, Nursimulu N, Tyagi A, Culp-Hill R, et al
    Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.
    Blood. 2025 Aug 26:blood.2025029132. doi: 10.1182/blood.2025029132.
    >> Share

  86. CHENG W, Yi X, Wang Z, Li JF, et al
    Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
    Blood. 2025 Aug 19:blood.2024027692. doi: 10.1182/blood.2024027692.
    >> Share

  87. MONTEFIORI LE, Iacobucci I, Gao Q, Moore J, et al
    Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
    Blood. 2025 Aug 14:blood.2025028985. doi: 10.1182/blood.2025028985.
    >> Share

  88. ZHOU X, Chen J, Tang YL, Sun H, et al
    Epidemiology, Clinical Features, and Molecular Basis of TTMV::RARA-driven Acute Promyelocytic Leukemia.
    Blood. 2025 Aug 14:blood.2025028674. doi: 10.1182/blood.2025028674.
    >> Share

  89. ANNESLEY C, Seidel K, Wu Q, Summers C, et al
    Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
    Blood. 2025;146:789-801.
    >> Share

  90. CHEN S, Xiao Z
    Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation.
    Blood. 2025;146:765.
    >> Share

  91. ABRUZZESE E, Chelysheva E
    How I Manage Chronic Myeloid Leukemia During Pregnancy.
    Blood. 2025 Aug 4:blood.2024026513. doi: 10.1182/blood.2024026513.
    >> Share

  92. PAULI C, Kienhofer M, Blank MF, Begik O, et al
    Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.
    Blood. 2025 Aug 1:blood.2024027822. doi: 10.1182/blood.2024027822.
    >> Share

    July 2025
  93. DAVER N, Vyas P, Huls G, Dohner H, et al
    The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
    Blood. 2025;146:601-611.
    >> Share

  94. SMITH A, Denny NDR, Chahrour C, Sharp K, et al
    Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.
    Blood. 2025 Jul 29:blood.2024028019. doi: 10.1182/blood.2024028019.
    >> Share

  95. UMEDA M, Hiltenbrand RL, Michmerhuizen NL, Barajas JM, et al
    Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia.
    Blood. 2025 Jul 23:blood.2025028993. doi: 10.1182/blood.2025028993.
    >> Share

  96. JI Y, Huang Y, Thomas T, Kapti EG, et al
    CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis.
    Blood. 2025 Jul 23:blood.2024026271. doi: 10.1182/blood.2024026271.
    >> Share


  97. Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756-768.
    Blood. 2025;146:397.
    >> Share

  98. CHENG J, Zhou J
    Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?
    Blood. 2025;146:396.
    >> Share

  99. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
    Blood. 2025;146:291-303.
    >> Share

  100. WANG Z, Skwarska A, Poigaialwar G, Chaudhry S, et al
    Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
    Blood. 2025;146:341-355.
    >> Share

  101. GOEL P, Aryal S, Franceski AM, Kuznetsova V, et al
    The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFkappaB signaling.
    Blood. 2025 Jul 15:blood.2024028199. doi: 10.1182/blood.2024028199.
    >> Share

  102. GRAINGER BT, Thompson PA, Cheah CY
    Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia.
    Blood. 2025;146:145-154.
    >> Share

  103. CARTER BZ, Mak PY, Ayoub E, Wu X, et al
    Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
    Blood. 2025 Jul 3:blood.2025028935. doi: 10.1182/blood.2025028935.
    >> Share

  104. MOHAMED A, Richardson AI
    Therapy-related juvenile myelomonocytic leukemia.
    Blood. 2025;146:127.
    >> Share

    June 2025
  105. DEB PQ, Zhang X
    B-lymphoblastic leukemia with KMT2A rearrangement with mature B-cell phenotype and surface lambda light-chain restriction.
    Blood. 2025;145:3194.
    >> Share

  106. REVILLE PK, Wang B, Marvin-Peek J, Yuan B, et al
    Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
    Blood. 2025;145:3015-3029.
    >> Share

  107. LUGER SM
    Introduction to a Blood Spotlight series on acute myeloid leukemia.
    Blood. 2025;145:2801-2802.
    >> Share

  108. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    >> Share

  109. COURTOIS L, Pinton A, Cabannes-Hamy A, Simonin M, et al
    Surface pTalpha expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.
    Blood. 2025;145:2903-2913.
    >> Share

  110. PERL AE
    Approaching a therapeutic inflection point for FLT3-mutated AML.
    Blood. 2025;145:2834-2839.
    >> Share

  111. CHEN C, Xu J, Sussman JH, Vincent T, et al
    Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.
    Blood. 2025;145:2685-2700.
    >> Share

  112. KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al
    The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
    Blood. 2025;145:2733-2745.
    >> Share

  113. WIERDA WG, Eichhorst BF, Hallek MJ
    Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia.
    Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570.
    >> Share

    May 2025
  114. LU J, Xue SL, Wang Y, He XF, et al
    Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
    Blood. 2025;145:2645-2655.
    >> Share

  115. EGAN G, Tasian SK
    Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements.
    Blood. 2025;145:2574-2586.
    >> Share

  116. ESCHERICH CS, Li Z, Barnett KR, Li Y, et al
    Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin.
    Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215.
    >> Share

  117. MAYDAY MY, Biancon G, Wei M, Ramirez C, et al
    RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation.
    Blood. 2025 May 28:blood.2024027712. doi: 10.1182/blood.2024027712.
    >> Share

  118. JUM'AH H, Viswanatha D
    Classic hairy cell leukemia and concomitant smoldering myeloma.
    Blood. 2025;145:2533.
    >> Share

  119. BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al
    Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
    Blood. 2025;145:2447-2459.
    >> Share

  120. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    >> Share

  121. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    >> Share

  122. SAORIN A, Dehler A, Galvan B, Steffen FD, et al
    Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.
    Blood. 2025 May 13:blood.2025028938. doi: 10.1182/blood.2025028938.
    >> Share

  123. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
    Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
    Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
    >> Share

  124. ALDOSS I, Clark MC, Forman SJ
    How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy.
    Blood. 2025 May 12:blood.2024027267. doi: 10.1182/blood.2024027267.
    >> Share

  125. CHALANDON Y, Simonetta F, Masouridi-Levrat S
    How I approach hematopoietic stem cell transplantation for CML in a TKI world.
    Blood. 2025 May 12:blood.2024026512. doi: 10.1182/blood.2024026512.
    >> Share

  126. HOURIGAN CS
    From prognostication to precision in acute myeloid leukemia.
    Blood. 2025;145:2105-2106.
    >> Share


  127. Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
    Blood. 2025;145:2231.
    >> Share

  128. LEVIS MJ, Hamadani M, Logan BR, Jones RJ, et al
    Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
    Blood. 2025;145:2138-2148.
    >> Share

  129. GOOPTU M, Murdock HM, Soiffer RJ
    How I treat AML relapse after allogeneic HSCT.
    Blood. 2025;145:2128-2137.
    >> Share

  130. TEFFERI A, Fathima S, Abdelmagid M, Alsugair A, et al
    BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia.
    Blood. 2025 May 7:blood.2024027170. doi: 10.1182/blood.2024027170.
    >> Share

  131. ARELLANO ML, Thirman MJ, DiPersio JF, Heiblig M, et al
    Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
    Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357.
    >> Share

  132. BULLINGER L
    Mixed-phenotype acute leukemia revisited: omics lead the way.
    Blood. 2025;145:1969-1971.
    >> Share

    April 2025
  133. MCMAHON CM
    Beyond conVENtional 7+3 in acute myeloid leukemia.
    Blood. 2025;145:1831-1832.
    >> Share

  134. GARCIAZ S
    STINGing leukemia stem cells through PSTK inhibition.
    Blood. 2025;145:1833-1835.
    >> Share

  135. ZHANG W, Cai J, Wang X, Ma Y, et al
    Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
    Blood. 2025;145:1890-1902.
    >> Share

  136. PODVIN B, Hardeman A
    Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic cell proliferation.
    Blood. 2025;145:1827.
    >> Share

  137. CHAKRABORTY SR, Karrs JX
    A rare case of nodal hairy cell leukemia exhibiting characteristic morphological and immunohistochemical features.
    Blood. 2025;145:1826.
    >> Share

  138. DE KESEL J, Fijalkowski I, Pieters T, Borin C, et al
    HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia.
    Blood. 2025 Apr 15:blood.2024026848. doi: 10.1182/blood.2024026848.
    >> Share

  139. DAVIDS MS, Kenderian SS, Flinn IW, Hill BT, et al
    ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2025 Apr 10:blood.2024027460. doi: 10.1182/blood.2024027460.
    >> Share

  140. TURHAN AG
    SMAC mimetics in action in chronic myeloid leukemia.
    Blood. 2025;145:1596-1597.
    >> Share


  141. Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597-605.
    Blood. 2025;145:1703-1705.
    >> Share

  142. SILBERT SK, Rankin AW, Hoang CN, Semchenkova A, et al
    Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
    Blood. 2025 Apr 7:blood.2024026655. doi: 10.1182/blood.2024026655.
    >> Share

  143. DOMBRET H
    Introduction to a review series on acute lymphoblastic leukemia.
    Blood. 2025;145:1439.
    >> Share

  144. RAMPOTAS A, Roddie C
    The present and future of CAR T-cell therapy for adult B-cell ALL.
    Blood. 2025;145:1485-1497.
    >> Share

    March 2025
  145. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    >> Share

  146. CALO-PEREZ A, Martinez-Fernandez R
    Atypical chronic myeloid leukemia: from cytology to molecular characterization.
    Blood. 2025;145:1438.
    >> Share

  147. ROTHFUSS C, Baumann T, Donakonda S, Brauchle B, et al
    Two-layered immune escape in AML is overcome by Fcgamma receptor activation and inhibition of PGE2 signaling in NK cells.
    Blood. 2025;145:1395-1406.
    >> Share

  148. HAN Q, Gu Y, Xiang H, Zhang L, et al
    Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
    Blood. 2025;145:1407-1421.
    >> Share

  149. CHEN J, Suttorp M, Hijiya N
    How I treat chronic myeloid leukemia in children and adolescents.
    Blood. 2025 Mar 25:blood.2024026514. doi: 10.1182/blood.2024026514.
    >> Share

  150. KOTROVA M, Proske C, Darzentas N, Laqua A, et al
    NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.
    Blood. 2025 Mar 25:blood.2024027175. doi: 10.1182/blood.2024027175.
    >> Share

  151. LUGER SM
    Introduction to a How I Treat series on acute myeloid leukemia.
    Blood. 2025;145:1227-1228.
    >> Share

  152. FURSTENAU M, Robrecht S, Schneider C, Tausch E, et al
    MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
    Blood. 2025;145:1282-1292.
    >> Share

  153. WEI AH, Loo S, Daver N
    How I treat patients with AML using azacitidine and venetoclax.
    Blood. 2025;145:1237-1250.
    >> Share

  154. LUO Q, Fortune AL, Lane AA
    PI3Kgamma in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
    Blood. 2025 Mar 19:blood.2024027376. doi: 10.1182/blood.2024027376.
    >> Share

  155. XU J, Sussman JH, Yang A, Yoshimura S, et al
    STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor sensitivity in T-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 18:blood.2025028566. doi: 10.1182/blood.2025028566.
    >> Share

  156. DALGETTY M, Cortes J
    Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
    Blood. 2025 Mar 18:blood.2024027944. doi: 10.1182/blood.2024027944.
    >> Share

  157. FALGAS A, Lazaro-Gorines R, Zanetti SR, Rubio-Perez L, et al
    A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 16:blood.2024025440. doi: 10.1182/blood.2024025440.
    >> Share

  158. WANG WJ, Loghavi S
    Acute myeloid leukemia with RUNX1::CBFA2T3 fusion.
    Blood. 2025;145:1226.
    >> Share

  159. WULIJI N, Jones SMW, Gooley TA, Gerds AT, et al
    Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
    Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543.
    >> Share

  160. TAM CS, Balendran S, Blombery P
    Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
    Blood. 2025;145:1005-1009.
    >> Share

    February 2025
  161. ZEIDNER JF, Sallman DA, Recher C, Daver NG, et al
    Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
    Blood. 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408.
    >> Share

  162. TAMIRO F, Padovano C, De Santis E, Di Iasio S, et al
    NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance.
    Blood. 2025 Feb 26:blood.2024027020. doi: 10.1182/blood.2024027020.
    >> Share

  163. CONDOLUCI A, Romano I, Dietrich D, Pini K, et al
    Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17.
    Blood. 2025 Feb 26:blood.2024026879. doi: 10.1182/blood.2024026879.
    >> Share

  164. ALLEN B, Bottomly D, Kohnke T, Wang A, et al
    A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.
    Blood. 2025 Feb 26:blood.2024028239. doi: 10.1182/blood.2024028239.
    >> Share

  165. LINDER A, Nixdorf D, Kuhl N, Piseddu I, et al
    STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia.
    Blood. 2025 Feb 26:blood.2024026934. doi: 10.1182/blood.2024026934.
    >> Share

  166. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    >> Share

  167. PARISI X, Loghavi S
    Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype.
    Blood. 2025;145:784.
    >> Share

  168. SHAH V, Giotopoulos G, Osaki H, Meyerhofer M, et al
    Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
    Blood. 2025;145:748-764.
    >> Share

  169. SILVA HJ, Martin G, Birocchi F, Wehrli M, et al
    CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
    Blood. 2025;145:720-731.
    >> Share

  170. MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al
    Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
    Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700.
    >> Share

  171. SHEN Q, Hu S
    Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
    Blood. 2025;145:652.
    >> Share

  172. FISKUS W, Mill CP, Bose P, Masarova L, et al
    Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
    Blood. 2025;145:612-624.
    >> Share

  173. HE L, Zhao T, Leong WZ, Sharda A, et al
    PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells.
    Blood. 2025 Feb 5:blood.2024026040. doi: 10.1182/blood.2024026040.
    >> Share

    January 2025
  174. LYAPICHEV KA, Behdad A
    c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation.
    Blood. 2025;145:547.
    >> Share

  175. POHLY MF, Putzker K, Scheinost S, Ben Taarit L, et al
    IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
    Blood. 2025 Jan 27:blood.2024027171. doi: 10.1182/blood.2024027171.
    >> Share

  176. ABEDIN SM, Uy GL, Michaelis LC
    The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment.
    Blood. 2025 Jan 24:blood.2024026004. doi: 10.1182/blood.2024026004.
    >> Share

  177. CHAPAPRIETA V, Maiques-Diaz A, Nadeu F, Clot G, et al
    Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia.
    Blood. 2025 Jan 22:blood.2024025396. doi: 10.1182/blood.2024025396.
    >> Share

  178. ALIKARAMI F, Xie HM, Riedel SS, Goodrow H, et al
    GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
    Blood. 2025 Jan 22:blood.2024025761. doi: 10.1182/blood.2024025761.
    >> Share

  179. LYU J, Liu Y, Liu N, Vu H, et al
    CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia.
    Blood. 2025 Jan 22:blood.2024027207. doi: 10.1182/blood.2024027207.
    >> Share

  180. SCHAFER HACKENHAAR F, Refhagen N, Hagleitner MM, van Leeuwen FN, et al
    CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027.
    >> Share

  181. ARAUJO JL, Wagenblast E, Voisin V, McLeod J, et al
    FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
    Blood. 2025 Jan 22:blood.2024025886. doi: 10.1182/blood.2024025886.
    >> Share

  182. GALERA P, Dilip D, Derkach A, Chan A, et al
    Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype.
    Blood. 2025 Jan 15:blood.2024026273. doi: 10.1182/blood.2024026273.
    >> Share

  183. RONNACKER J, Grau M, Klasmeier M, Klesse C, et al
    Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia.
    Blood. 2025 Jan 15:blood.2024026886. doi: 10.1182/blood.2024026886.
    >> Share

  184. NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
    Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286.
    >> Share

  185. PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al
    Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
    Blood. 2025;145:190-201.
    >> Share

  186. DING YY, Sussman JH, Madden K, Loftus JP, et al
    Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482.
    >> Share

  187. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    >> Share

  188. DOMBRET H
    Introduction to a How I Treat series on acute lymphoblastic leukemia.
    Blood. 2025;145:1-2.
    >> Share

  189. CHIARETTI S, Foa R
    How I treat adult Ph+ ALL.
    Blood. 2025;145:11-19.
    >> Share

  190. LAMBLE AJ, Kovach AE, Shah NN
    How I treat postimmunotherapy relapsed B-ALL.
    Blood. 2025;145:64-74.
    >> Share

    December 2024
  191. PASSET M, Kim R, Clappier E
    Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
    Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919.
    >> Share

  192. CRUZ-RODRIGUEZ N, Deininger MW
    Novel Treatment Strategies for Chronic Myeloid Leukemia.
    Blood. 2024 Dec 27:blood.2024026312. doi: 10.1182/blood.2024026312.
    >> Share

  193. ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al
    DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085.
    >> Share

  194. MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al
    alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
    Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245.
    >> Share

  195. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    >> Share

  196. LACHOWIEZ CA, Ravikumar VI, Othman J, O'Nions J, et al
    Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
    Blood. 2024;144:2788-2792.
    >> Share

  197. BROWN JR, Eichhorst B, Lamanna N, O'Brien SM, et al
    Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
    Blood. 2024;144:2706-2717.
    >> Share

  198. HULS GA, Woolthuis CM, Schuringa JJ
    Menin inhibitors in the treatment of acute myeloid leukemia.
    Blood. 2024 Dec 24:blood.2024026232. doi: 10.1182/blood.2024026232.
    >> Share

  199. ARONS E, Tai CH, Suraj J, Liu Y, et al
    Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.
    Blood. 2024 Dec 24:blood.2024026894. doi: 10.1182/blood.2024026894.
    >> Share

  200. CUI B, Ai L, Lei M, Duan Y, et al
    Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia.
    Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
    >> Share

  201. BOUDIA F, Baille M, Babin L, Aid Z, et al
    Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
    Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
    >> Share

  202. HAUBNER S, Subklewe M, Sadelain M
    Honing CAR T cells to tackle acute myeloid leukemia.
    Blood. 2024 Dec 4:blood.2024024063. doi: 10.1182/blood.2024024063.
    >> Share

    November 2024
  203. GOLDFINGER M, Mantzaris I, Shastri A, Saunthararajah Y, et al
    A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
    Blood. 2024;144:2360-2363.
    >> Share

  204. DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al
    Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
    Blood. 2024;144:2169-2173.
    >> Share

  205. DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al
    Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
    Blood. 2024;144:2211-2222.
    >> Share

  206. MA J, Wang Z, Mintzlaff D, Zhang H, et al
    Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277.
    >> Share

  207. NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al
    Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
    Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910.
    >> Share

  208. LU P, Zhang X, Yang J, Li J, et al
    Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
    Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861.
    >> Share


  209. Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140(25):2663-2671.
    Blood. 2024;144:2068.
    >> Share

  210. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    >> Share

  211. HUNTER AM, Patnaik MM, Itzykson R, Mesa R, et al
    Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
    Blood. 2024;144:1987-1992.
    >> Share

  212. LOPEZ-MILLAN B, Rubio-Gayarre A, Vinyoles M, Trincado JL, et al
    NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.
    Blood. 2024;144:2002-2017.
    >> Share

  213. VOSO MT, Guarnera L, Lehmann S, Dohner K, et al
    Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
    Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186.
    >> Share

  214. GUILHOT F, Hehlmann R
    Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.
    Blood. 2024 Nov 1:blood.2024026311. doi: 10.1182/blood.2024026311.
    >> Share

    October 2024
  215. LUO MX, Tan T, Trussart M, Poch A, et al
    Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
    Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341.
    >> Share

  216. WU Q, Chen D
    Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus.
    Blood. 2024;144:1846.
    >> Share

  217. KIM E, Chen SS, Sivina M, Hwang H, et al
    Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
    Blood. 2024 Oct 23:blood.2024025683. doi: 10.1182/blood.2024025683.
    >> Share

  218. LIU Y, Bollino DR, Bah OM, Strovel ET, et al
    A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia.
    Blood. 2024 Oct 22:blood.2024024837. doi: 10.1182/blood.2024024837.
    >> Share

  219. GOKBUGET N, Steffen B
    How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia.
    Blood. 2024 Oct 11:blood.2023023156. doi: 10.1182/blood.2023023156.
    >> Share

  220. KWOK M, Stankovic T
    Targeting therapeutic vulnerabilities in T-PLL.
    Blood. 2024;144:1548-1550.
    >> Share

  221. NIEDER R, Li W
    Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia with P2RY8::CRLF2 fusion.
    Blood. 2024;144:1646.
    >> Share

  222. VON JAN J, Timonen S, Braun T, Jiang Q, et al
    Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
    Blood. 2024;144:1595-1610.
    >> Share

  223. SIMONIN M, Vasseur L, Lengline E, Lhermitte L, et al
    NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
    Blood. 2024;144:1570-1580.
    >> Share

  224. NEWMAN H, Teachey DT
    A T-ALL order: a new risk classifier for T-ALL.
    Blood. 2024;144:1545-1547.
    >> Share

  225. ROBOZ GJ, Canaani J
    How I use Maintenance Therapy in Acute Myeloid Leukemia.
    Blood. 2024 Oct 7:blood.2024024010. doi: 10.1182/blood.2024024010.
    >> Share

  226. LUSKIN MR, Murakami MA, Keating JH, Flamand Y, et al
    Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
    Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800.
    >> Share

  227. ZHOU X, Chen X, Chen J, Wen L, et al
    Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL.
    Blood. 2024;144:1471-1485.
    >> Share

  228. POLONEN P, Mullighan CG, Teachey DT
    Classification and risk stratification in T-lineage acute lymphoblastic leukemia.
    Blood. 2024 Oct 2:blood.2023022920. doi: 10.1182/blood.2023022920.
    >> Share

  229. KYTOLA S, Vanttinen IM, Ruokoranta T, Partanen A, et al
    Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
    Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.
    >> Share

  230. GREEN SD, Wang ES
    How I Treat: Secondary Acute Myeloid Leukemia.
    Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011.
    >> Share

    September 2024
  231. POCOCK R, Mansour MR
    T-ALL and T-LBL: a notch apart.
    Blood. 2024;144:1356-1357.
    >> Share

  232. LI Z, Meng G
    Targeting DUX4-r leukemia via PI3K and CD371.
    Blood. 2024;144:1354-1356.
    >> Share

  233. SHARMAN JP
    Pirtobrutinib combinations in CLL.
    Blood. 2024;144:1351-1352.
    >> Share

  234. THORSSON H, Henningsson R, Puente-Moncada N, Pena-Martinez P, et al
    Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases.
    Blood. 2024;144:1399-1411.
    >> Share

  235. ROEKER LE, Woyach JA, Cheah CY, Coombs CC, et al
    Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Blood. 2024;144:1374-1386.
    >> Share

  236. RAHMAN S, Bloye G, Farah N, Demeulemeester J, et al
    Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.
    Blood. 2024 Sep 24:blood.2024024300. doi: 10.1182/blood.2024024300.
    >> Share

  237. JIN Q, Harris E, Myers JA, Mehmood R, et al
    Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia.
    Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281.
    >> Share

  238. LOO S, Potter N, Ivey A, O'Nions J Dr, et al
    Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
    Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605.
    >> Share

  239. WANG ES
    Curing APL in Latin America: more than just ATRA.
    Blood. 2024;144:1237-1238.
    >> Share

  240. BONADIES N
    SHERLOCK unmasks fusion-driven leukemias.
    Blood. 2024;144:1241-1243.
    >> Share

  241. VEDULA RS, Karp HQ, Koob J, Lim F, et al
    CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
    Blood. 2024;144:1290-1299.
    >> Share

  242. PENTER L, Wu CJ
    Therapy response in AML: a tale of two T cells.
    Blood. 2024;144:1134-1136.
    >> Share

  243. KWON MC, Thuring JW, Querolle O, Dai X, et al
    Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Blood. 2024;144:1206-1220.
    >> Share

  244. WALTER RB, Potter V, Craddock C
    Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old.
    Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247.
    >> Share

  245. BADAR T, Luger SM, Litzow MR
    Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
    Blood. 2024 Sep 5:blood.2023022921. doi: 10.1182/blood.2023022921.
    >> Share

  246. SALLMAN DA, Stahl M
    TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
    Blood. 2024 Sep 5:blood.2024024245. doi: 10.1182/blood.2024024245.
    >> Share

  247. FALKENBURG JHF, Heemskerk MHM
    TCR targeting hematopoiesis to cure leukemia.
    Blood. 2024;144:1031-1033.
    >> Share

    August 2024
  248. SUMMERS RJ, Teachey DT
    SNPing away poor outcomes in T-ALL.
    Blood. 2024;144:924-925.
    >> Share

  249. EADIE LN, Lagonik E, Page EC, Schutz CE, et al
    Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
    Blood. 2024;144:1022-1026.
    >> Share

  250. BALDUCCI E, Simonin M, Duployez N, Steimle T, et al
    Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
    Blood. 2024;144:988-1000.
    >> Share

  251. WADHWA A, Chen Y, Hageman L, Angiolillo A, et al
    Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report.
    Blood. 2024 Aug 27:blood.2024024455. doi: 10.1182/blood.2024024455.
    >> Share

  252. COBALEDA C, Sanchez-Garcia I
    Childhood leukemia prevention within reach.
    Blood. 2024;144:799-800.
    >> Share

  253. INGELFINGER F
    Hijacking T helper cells for AML progression.
    Blood. 2024;144:804-805.
    >> Share

  254. XU Z, Padmore R
    AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest.
    Blood. 2024;144:918.
    >> Share

  255. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
    Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
    Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
    >> Share

  256. ZHOU X, Zhang L, Aryal S, Veasey V, et al
    Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia.
    Blood. 2024 Aug 16:blood.2023023644. doi: 10.1182/blood.2023023644.
    >> Share

  257. HU Z, Ok CY
    Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS.
    Blood. 2024;144:794.
    >> Share

  258. ITZYKSON R
    NPM1-mutated AML: how many diseases?
    Blood. 2024;144:681-683.
    >> Share

  259. OTHMAN J, Potter N, Ivey A, Tazi Y, et al
    Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
    Blood. 2024;144:714-728.
    >> Share

  260. LEYTE-VIDAL A, Garrido Ruiz D, DeFilippis R, Leske IB, et al
    BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Blood. 2024;144:639-645.
    >> Share

  261. YEUNG DT, Shanmuganathan N, Reynolds J, Branford S, et al
    Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
    Blood. 2024 Aug 5:blood.2024024657. doi: 10.1182/blood.2024024657.
    >> Share

  262. ARRIETA-BOLANOS E, van der Burg LLJ, Gedde-Dahl T, Robin M, et al
    Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
    Blood. 2024 Aug 5:blood.2024024351. doi: 10.1182/blood.2024024351.
    >> Share


  263. Metzeler KH, Herold T, Rothenberg-Turley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.
    Blood. 2024;144:589.
    >> Share

  264. MOSS P
    A tumor suppressor of CLL: all (T-)bets are on.
    Blood. 2024;144:467-469.
    >> Share

  265. COOK JA, Lott L, Perry J, Eckel AM, et al
    Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
    Blood. 2024;144:581-585.
    >> Share

  266. EFFICACE F, Kicinski M, Coens C, Suciu S, et al
    Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
    Blood. 2024;144:541-551.
    >> Share

    July 2024
  267. ZHANG X, Liu B, Huang J, Zhang YL, et al
    A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
    Blood. 2024 Jul 24:blood.2024024761. doi: 10.1182/blood.2024024761.
    >> Share

  268. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
    Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
    Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
    >> Share


  269. van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
    Blood. 2024;144:341.
    >> Share


  270. Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
    Blood. 2024;144:342.
    >> Share

  271. RADICH J
    Transplant, MRD, and predicting relapse in AML.
    Blood. 2024;144:245-247.
    >> Share

  272. OPAT S
    Treatment of relapsed CLL "in the BAAG"?
    Blood. 2024;144:243-244.
    >> Share

  273. MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al
    How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Blood. 2024;144:253-261.
    >> Share

  274. FURSTENAU M, Giza A, Weiss J, Kleinert F, et al
    Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
    Blood. 2024;144:272-282.
    >> Share

  275. WEI Q, Xu J
    Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
    Blood. 2024;144:238.
    >> Share

  276. HOURIGAN CS
    How complete must an AML remission be?
    Blood. 2024;144:131-132.
    >> Share

  277. AL-SAWAF O, Robrecht S, Zhang C, Olivieri S, et al
    Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study.
    Blood. 2024 Jul 10:blood.2024024631. doi: 10.1182/blood.2024024631.
    >> Share

  278. ISSA GC, Stein EM, DiNardo CDD
    How I Treat: Differentiation Therapy in Acute Myeloid Leukemia.
    Blood. 2024 Jul 8:blood.2024024008. doi: 10.1182/blood.2024024008.
    >> Share

  279. SUO S, Zhao D, Li F, Zhang Y, et al
    Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Jul 5:blood.2023023400. doi: 10.1182/blood.2023023400.
    >> Share

  280. SRINAGESH HK, Jackson C, Shiraz P, Jeyakumar N, et al
    A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952.
    >> Share

  281. LUM SH, Eikema DJ, Piepenbroek B, Wynn R, et al
    Outcome of Hematopoietic Stem Cell Transplantation in 813 Pediatric Patients with Fanconi Anemia.
    Blood. 2024 Jul 5:blood.2023022751. doi: 10.1182/blood.2023022751.
    >> Share

  282. QIAN Z, Yu F
    GADD45A: a key tumor suppressor in AML subtypes.
    Blood. 2024;144:6-7.
    >> Share

  283. ZHAO Y, Short NJ, Kantarjian HM, Chang TC, et al
    Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
    Blood. 2024;144:61-73.
    >> Share

    June 2024
  284. RADPOUR R, Simillion C, Wang B, Abbas HA, et al
    IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion.
    Blood. 2024 Jun 28:blood.2024024000. doi: 10.1182/blood.2024024000.
    >> Share

  285. BIDOT S, Feldman AL
    Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2024;143:2808.
    >> Share

  286. LENK L, Baccelli I, Laqua A, Heymann J, et al
    The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
    Blood. 2024;143:2735-2748.
    >> Share

  287. LIN HY, Mohammadhosseini M, McClatchy J, Villamor-Paya M, et al
    The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated AML progression.
    Blood. 2024;143:2749-2762.
    >> Share

  288. WALCZAK P, Fodil S, Vignal N, Cabannes-Hamy A, et al
    Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
    Blood. 2024 Jun 25:blood.2024024838. doi: 10.1182/blood.2024024838.
    >> Share

  289. BARTRAM J, Ancliff P, Vora A
    How I Treat on Infant Acute Lymphoblastic Leukemia.
    Blood. 2024 Jun 21:blood.2023023154. doi: 10.1182/blood.2023023154.
    >> Share


  290. Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]
    Blood. 2024;143:2676.
    >> Share

  291. FORCONI F
    Time for a new prognostic score in CLL?
    Blood. 2024;143:2561-2562.
    >> Share

  292. GAO Q, Harrison CJ
    B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c.
    Blood. 2024;143:2672.
    >> Share

  293. SATO T, Yoshida K, Toki T, Kanezaki R, et al
    Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
    Blood. 2024;143:2627-2643.
    >> Share

  294. FARROKHI A, Atre T, Salitra S, Aletaha M, et al
    Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Blood. 2024 Jun 14:blood.2024025038. doi: 10.1182/blood.2024025038.
    >> Share

  295. SANZ J, Labopin M, Choi G, Kulagin A, et al
    Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
    Blood. 2024;143:2534-2543.
    >> Share

  296. MARCHAND T, Lamy de La Chapelle T, Loughran TP
    A modern view of LGL leukemia.
    Blood. 2024 Jun 7:blood.2023021790. doi: 10.1182/blood.2023021790.
    >> Share

  297. LUSKIN MR
    Finding the perPh+ect balance in Ph+ ALL.
    Blood. 2024;143:2339-2340.
    >> Share

    May 2024
  298. KANG YA
    Awakening your innate power to combat AML.
    Blood. 2024;143:2223-2224.
    >> Share

  299. HALL T, Gurbuxani S, Crispino JD
    Malignant progression of preleukemic disorders.
    Blood. 2024;143:2245-2255.
    >> Share

  300. ONIDA F, Gagelmann N, Chalandon Y, Kobbe G, et al
    Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
    Blood. 2024;143:2227-2244.
    >> Share

  301. KOURY LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, et al
    Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
    Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890.
    >> Share

  302. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
    CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
    Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
    >> Share

  303. SAWYER EM, Kraft AS
    SMACing down relapsed T-ALL.
    Blood. 2024;143:2116-2117.
    >> Share

  304. MAZZIOTTA F, Biavati L, Rimando JC, Rutella S, et al
    CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia.
    Blood. 2024 May 22:blood.2023021680. doi: 10.1182/blood.2023021680.
    >> Share

  305. LEWIS RI, Vom Stein AF, Hallek MJ
    Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
    Blood. 2024 May 22:blood.2023022861. doi: 10.1182/blood.2023022861.
    >> Share

  306. WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
    Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
    Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
    >> Share


  307. MRD and EFS in pediatric T-lymphoblastic lymphoma.
    Blood. 2024;143:2111.
    >> Share


  308. Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
    Blood. 2024;143:2108-2110.
    >> Share

  309. RIBERA JM
    MRD: also for T-lymphoblastic lymphoma.
    Blood. 2024;143:2017-2019.
    >> Share

  310. TAMENI A, Toffalori C, Vago L
    Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant.
    Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962.
    >> Share

  311. LE RQ, Przepiorka D, Chen H, Shen YL, et al
    Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
    Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313.
    >> Share

  312. RECHER C
    Transplant in AML: just follow the NPM1 guide!
    Blood. 2024;143:1881-1882.
    >> Share

  313. SUNG PJ
    PIKing the right target in AML.
    Blood. 2024;143:1884-1885.
    >> Share

  314. OTHMAN J, Potter N, Ivey A, Jovanovic J, et al
    Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
    Blood. 2024;143:1931-1936.
    >> Share

  315. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
    Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
    Blood. 2024;143:1903-1930.
    >> Share

  316. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
    Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
    Blood. 2024;143:1891-1902.
    >> Share

    April 2024
  317. ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
    T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
    Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
    >> Share

  318. KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
    HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
    Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
    >> Share

  319. WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
    Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
    Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
    >> Share

  320. SUBKLEWE M
    T cells take aim in AML: targeting IDH2.
    Blood. 2024;143:1681-1682.
    >> Share

  321. ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
    Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
    Blood. 2024;143:1752-1757.
    >> Share

  322. TRAN TH, Tasian SK
    How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
    Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
    >> Share

  323. LAMBLE AJ, Rau RE
    IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
    Blood. 2024;143:1556-1557.
    >> Share

  324. CUNEO A, Ghia P
    Ibrutinib in CLL: benefit for all?
    Blood. 2024;143:1558-1559.
    >> Share

  325. BUFFET R
    How lipid coating soothes the gut in AML therapy.
    Blood. 2024;143:1559-1561.
    >> Share

  326. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
    CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
    Blood. 2024;143:1628-1645.
    >> Share

  327. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
    Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
    Blood. 2024;143:1616-1627.
    >> Share

  328. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
    Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
    >> Share

  329. BULLINGER L, Kronke J
    Making AML fly too close to the sun.
    Blood. 2024;143:1438-1439.
    >> Share

  330. BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
    Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Blood. 2024;143:1513-1527.
    >> Share

  331. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
    Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
    Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
    >> Share

  332. HASSAN N, Yi H, Malik B, Gaspard-Boulinc LC, et al
    Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.
    Blood. 2024 Apr 5:blood.2024024072. doi: 10.1182/blood.2024024072.
    >> Share

  333. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  334. MINA A, Greenberg PL, Deeg HJ
    How I reduce and treat posttransplant relapse of MDS.
    Blood. 2024;143:1344-1354.
    >> Share

  335. BASTIAN L, Beder T, Barz MJ, Bendig S, et al
    Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
    Blood. 2024;143:1391-1398.
    >> Share

    March 2024
  336. INESS AN, Bachireddy P
    GPR56 in GVL: marker or mechanism?
    Blood. 2024;143:1206-1207.
    >> Share

  337. MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
    The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
    Blood. 2024;143:1269-1281.
    >> Share

  338. BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
    Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
    Blood. 2024;143:1139-1156.
    >> Share

  339. KLEIN K, Kollmann S, Hiesinger A, List J, et al
    A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
    Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
    >> Share

  340. AZOULAY E, Maertens J, Lemiale V
    How I manage acute respiratory failure in patients with hematological malignancies.
    Blood. 2024;143:971-982.
    >> Share

  341. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
    Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
    Blood. 2024;143:1049-1054.
    >> Share

  342. FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
    Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
    Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
    >> Share

  343. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    >> Share

  344. CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
    Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
    >> Share


  345. Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
    Blood. 2024;143:939.
    >> Share

  346. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

  347. O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
    Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
    Blood. 2024;143:933-937.
    >> Share

  348. ESCHERICH CS, Chen W, Li Y, Yang W, et al
    Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
    Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
    >> Share

  349. AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
    Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
    >> Share

    February 2024
  350. BARROS PINTO MP, Cabecadas J
    Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
    Blood. 2024;143:833.
    >> Share

  351. MURTADHA M, Park M, Zhu Y, Caserta E, et al
    CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
    Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
    >> Share

  352. VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
    Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
    Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
    >> Share

  353. BARBOSA K, Deshpande A, Perales M, Xiang P, et al
    Transcriptional control of leukemogenesis by the chromatin reader SGF29.
    Blood. 2024;143:697-712.
    >> Share

  354. BISWAS J, Abdel-Wahab O
    A new SAGA for AML: targeting SGF29 in AML.
    Blood. 2024;143:657-658.
    >> Share

  355. SUMMERS RJ, Teachey DT, Hunger SP
    How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
    Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
    >> Share

  356. MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
    CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
    Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
    >> Share

  357. FISKUS W, Piel J, Collins MP, Hentemann M, et al
    BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
    Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
    >> Share

  358. COTY-FATTAL Z, Richardson AI
    A 3-year-old with chronic myeloid leukemia.
    Blood. 2024;143:651.
    >> Share

  359. BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
    Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
    Blood. 2024;143:619-630.
    >> Share

  360. BERNT KM
    Menin dependence: UBTF-ITD AML joins the club.
    Blood. 2024;143:567-569.
    >> Share

  361. CHEN B, Abdel-Wahab O
    Targeting the cBAF complex in T-ALL.
    Blood. 2024;143:566-567.
    >> Share

  362. ARBER C
    Two to tango: engineered T cells against AML.
    Blood. 2024;143:476-478.
    >> Share

  363. QIU L, Naresh KN
    Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
    Blood. 2024;143:561.
    >> Share

  364. DAO T, Xiong G, Mun SS, Meyerberg J, et al
    A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Blood. 2024;143:507-521.
    >> Share

  365. BHATT VR, Uy GL, Klepin HD
    Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
    Blood. 2024;143:483-487.
    >> Share

  366. ROUSSELOT P
    Old rivals become new friends.
    Blood. 2024;143:380-382.
    >> Share

  367. ORDONEZ MAZARIEGOS EE, Dimopoulos YP
    A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
    Blood. 2024;143:473.
    >> Share

    January 2024
  368. GU H, Chen C, Hou ZS, He XD, et al
    PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
    >> Share

  369. SCHRAW JM
    Anticancer drug exposure in utero and leukemia.
    Blood. 2024;143:293-294.
    >> Share

  370. BARATA JT
    Darwin, MSI2, and relapse in T-ALL.
    Blood. 2024;143:294-296.
    >> Share

  371. SAHASRABUDHE KD, Mims AS
    MRD in AML: who, what, when, where, and how?
    Blood. 2024;143:296-298.
    >> Share

  372. OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
    Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
    Blood. 2024;143:336-341.
    >> Share

  373. LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
    Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
    Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
    >> Share

  374. WEINACHT KG
    The rise of haplo: a quest for the perfect graft.
    Blood. 2024;143:193-195.
    >> Share


  375. alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
    Blood. 2024;143:291.
    >> Share

  376. CHEN H, Wang H
    Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
    Blood. 2024;143:290.
    >> Share

  377. SAULTIER P, Michel G
    How I Treat: long-term survivors of childhood acute leukemia.
    Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
    >> Share

  378. BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
    CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
    Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
    >> Share


  379. Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
    Blood. 2024;143:184.
    >> Share

  380. DIMOPOULOS YP, Loghavi S
    Acute leukemia of ambiguous lineage with BCL11B rearrangement.
    Blood. 2024;143:183.
    >> Share

  381. GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
    CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
    Blood. 2024;143:118-123.
    >> Share

  382. VELTMAAT L, Cortes J
    Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
    Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
    >> Share

  383. MOSS P
    Ibrutinib reversal of immune exhaustion in CLL.
    Blood. 2024;143:5-7.
    >> Share


  384. Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
    Blood. 2024;143:93.
    >> Share

  385. PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
    Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
    Blood. 2024;143:57-63.
    >> Share

    December 2023
  386. QUESSADA J, Loosveld M
    CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
    Blood. 2023;142:2332.
    >> Share

  387. HASSERJIAN RP, Germing U, Malcovati L
    Diagnosis and classification of myelodysplastic syndromes.
    Blood. 2023;142:2247-2257.
    >> Share

  388. DEZERN AE, Greenberg PL
    The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
    Blood. 2023;142:2258-2267.
    >> Share

  389. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  390. BRECCIA M
    A traffic light for TFR by lineage-specific MRD.
    Blood. 2023;142:2129-2130.
    >> Share

  391. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share


  392. NIH natural history study of FPDMM patients.
    Blood. 2023;142:2222.
    >> Share

  393. FRANK D, Patnana PK, Vorwerk J, Mao L, et al
    Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
    Blood. 2023;142:2175-2191.
    >> Share

  394. CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
    Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
    Blood. 2023;142:2146-2158.
    >> Share

  395. MARCELLINO BK
    PPM1D inhibition may allow us to WIP leukemia.
    Blood. 2023;142:2040-2042.
    >> Share

  396. COUSTAN-SMITH E, Conter V
    Closing the circle for ETP ALL.
    Blood. 2023;142:2039-2040.
    >> Share

  397. WOOD BL, Devidas M, Summers RJ, Chen Z, et al
    Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
    Blood. 2023;142:2069-2078.
    >> Share

  398. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
    Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
    Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
    >> Share

  399. PALM-APERGI C
    PLK4, a potential target against AML.
    Blood. 2023;142:1941-1942.
    >> Share

  400. STONE RM
    FLT(3)-ing about: the search for the best inhibitor.
    Blood. 2023;142:1937-1938.
    >> Share

  401. MAN CH, Lam W, Dang CC, Zeng XY, et al
    Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
    Blood. 2023;142:2002-2015.
    >> Share

  402. FLEMING S, Tsai XC, Morris R, Hou HA, et al
    TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
    Blood. 2023;142:2029-2033.
    >> Share

  403. LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
    Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
    Blood. 2023;142:1960-1971.
    >> Share

    November 2023
  404. BEWERSDORF JP, How J, Masarova L, Bose P, et al
    Moving toward disease modification in polycythemia vera.
    Blood. 2023;142:1859-1870.
    >> Share

  405. DAVIDS MS
    Functional cure reported in CLL.
    Blood. 2023;142:1761-1763.
    >> Share

  406. LIN E, Chen W
    Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
    Blood. 2023;142:1845.
    >> Share


  407. Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
    Blood. 2023;142:1846-1847.
    >> Share

  408. THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
    Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
    Blood. 2023;142:1784-1788.
    >> Share

  409. KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
    Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Blood. 2023;142:1806-1817.
    >> Share

  410. ROLLIG C
    Gemtuzumab ozogamicin in AML: the next chapter.
    Blood. 2023;142:1673-1674.
    >> Share

  411. STRASSER B, Haushofer A
    Cabot rings in chronic myelomonocytic leukemia.
    Blood. 2023;142:1757.
    >> Share

  412. FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
    Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
    Blood. 2023;142:1697-1707.
    >> Share


  413. Fractionated vs single-dose gemtuzumab for AML.
    Blood. 2023;142:1759.
    >> Share

  414. BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
    A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
    Blood. 2023;142:1752-1756.
    >> Share

  415. THOL FR, Dohner H, Ganser A
    How I treat refractory and relapsed acute myeloid leukemia.
    Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
    >> Share

  416. VYAS P
    Changing treatment changing prognosis of mutations.
    Blood. 2023;142:1583-1585.
    >> Share

  417. AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
    Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
    Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
    >> Share

    October 2023
  418. JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
    Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
    Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
    >> Share

  419. MALAGA ML, Carrillo LF
    FISH-negative, karyotype-negative acute promyelocytic leukemia.
    Blood. 2023;142:1328.
    >> Share

  420. PRINCE HM
    Blocked addiction to IL-15 for treating T-LGLL.
    Blood. 2023;142:1258-1260.
    >> Share

  421. XIE J, Bao X, Xue SL, Shen H, et al
    Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
    Blood. 2023;142:1323-1327.
    >> Share

  422. ZHANG J, Duan Y, Wu P, Chang Y, et al
    Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
    >> Share

  423. KUMAR J, Petrova-Drus K
    Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
    Blood. 2023;142:1253.
    >> Share

  424. CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
    Prevalence and significance of DDX41 gene variants in the general population.
    Blood. 2023;142:1185-1192.
    >> Share

  425. YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
    Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
    Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
    >> Share

    September 2023
  426. GOEDE V
    Frailty is also a target for targeted drugs in CLL.
    Blood. 2023;142:1107-1108.
    >> Share

  427. VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
    Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
    Blood. 2023;142:1131-1142.
    >> Share

  428. MERLI P, Algeri M, Galaverna F, Bertaina V, et al
    TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
    Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
    >> Share

  429. LI S, Adams PD
    Targeting the epichaperome to combat AML.
    Blood. 2023;142:1031-1032.
    >> Share


  430. Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
    Blood. 2023;142:1103.
    >> Share

  431. CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
    Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Blood. 2023;142:1056-1070.
    >> Share

  432. UCKELMANN HJ, Klusmann JH
    Double trouble: IRAK1/4 inhibitors in AML/MDS.
    Blood. 2023;142:945-946.
    >> Share

  433. KWOK M, Stankovic T
    CLL patients: GIVe me three!
    Blood. 2023;142:941-943.
    >> Share

  434. HUBER H, Tausch E, Schneider C, Edenhofer S, et al
    Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
    Blood. 2023;142:961-972.
    >> Share

  435. BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
    Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
    Blood. 2023;142:989-1007.
    >> Share

  436. FEI MY, Wang Y, Chang BH, Xue K, et al
    The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
    Blood. 2023;142:903-917.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016